Columbus Macro LLC raised its position in shares of AbbVie Inc (NYSE:ABBV) by 44.4% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 10,383 shares of the company’s stock after buying an additional 3,191 shares during the period. Columbus Macro LLC’s holdings in AbbVie were worth $919,000 as of its most recent filing with the Securities & Exchange Commission.
Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Investors Financial Group LLC purchased a new position in shares of AbbVie during the fourth quarter worth $214,000. Tsfg LLC raised its stake in shares of AbbVie by 13.4% in the fourth quarter. Tsfg LLC now owns 73,692 shares of the company’s stock valued at $6,525,000 after acquiring an additional 8,731 shares in the last quarter. Bremer Bank National Association raised its stake in shares of AbbVie by 41.7% in the fourth quarter. Bremer Bank National Association now owns 10,649 shares of the company’s stock valued at $943,000 after acquiring an additional 3,133 shares in the last quarter. JOYN Advisors Inc. acquired a new stake in shares of AbbVie in the fourth quarter valued at $249,000. Finally, Vantage Financial Partners Ltd. Inc. raised its stake in shares of AbbVie by 33.3% in the fourth quarter. Vantage Financial Partners Ltd. Inc. now owns 6,000 shares of the company’s stock valued at $531,000 after acquiring an additional 1,500 shares in the last quarter. Institutional investors and hedge funds own 70.46% of the company’s stock.
AbbVie stock opened at $84.02 on Tuesday. AbbVie Inc has a 1-year low of $62.66 and a 1-year high of $91.99. The stock has a market cap of $123.54 billion, a PE ratio of 38.72, a P/E/G ratio of 1.97 and a beta of 0.97. The stock’s fifty day moving average is $88.27 and its two-hundred day moving average is $77.67.
AbbVie (NYSE:ABBV) last posted its quarterly earnings results on Friday, November 1st. The company reported $2.33 earnings per share for the quarter, beating the Zacks’ consensus estimate of $2.29 by $0.04. AbbVie had a negative return on equity of 155.96% and a net margin of 9.90%. The company had revenue of $8.48 billion for the quarter, compared to analysts’ expectations of $8.37 billion. During the same period last year, the firm earned $2.14 earnings per share. AbbVie’s quarterly revenue was up 3.0% on a year-over-year basis. As a group, analysts anticipate that AbbVie Inc will post 8.95 earnings per share for the current year.
The firm also recently declared a — dividend, which will be paid on Friday, February 14th. Shareholders of record on Wednesday, January 15th will be paid a $1.18 dividend. The ex-dividend date is Tuesday, January 14th. This is a boost from AbbVie’s previous — dividend of $1.07. This represents a yield of 5.93%. AbbVie’s dividend payout ratio (DPR) is currently 59.67%.
Several analysts have recently issued reports on ABBV shares. Bank of America cut AbbVie from a “buy” rating to a “neutral” rating in a research note on Friday, January 3rd. Citigroup increased their price objective on AbbVie from $90.00 to $98.00 and gave the company a “buy” rating in a research note on Wednesday, November 20th. Piper Jaffray Companies increased their price objective on AbbVie from $81.00 to $90.00 in a research note on Friday, November 1st. UBS Group increased their price objective on AbbVie from $79.00 to $96.00 and gave the company a “buy” rating in a research note on Tuesday, November 19th. Finally, Cowen increased their price objective on AbbVie from $90.00 to $98.00 and gave the company an “outperform” rating in a research note on Thursday, December 26th. Three research analysts have rated the stock with a sell rating, six have given a hold rating and six have given a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus target price of $86.33.
AbbVie Company Profile
AbbVie Inc discovers, develops, manufactures, and sells pharmaceutical products in the United States, Japan, Germany, Canada, Italy, Spain, the Netherlands, the United Kingdom, Brazil, and internationally. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection.
Recommended Story: What is the definition of a trade war?
Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc (NYSE:ABBV).
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.